Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![autoimmne panel people]( "Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026")
Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 202610/12/2026At Meeting on the Mesa 2026, industry leaders discussed what it will take to move autoimmune CAR T beyond promising clinical results.
-
![Doctor holding patients hands-GettyImages-474808854]( "What LSPA's Life Sciences Future Says About The Road Ahead For CGT")
What LSPA's Life Sciences Future Says About The Road Ahead For CGT10/2/2026The LSPA’s Life Sciences Future 2026 highlighted how shifting capital, M&A, global competition, and commercial pressures are reshaping CGT.
-
![Aspirations, determination, goals, strategy-GettyImages-1296267263]( "Inside Scaling Next-Gen MSCs Without Scaling Risk")
Inside Scaling Next-Gen MSCs Without Scaling Risk9/25/2026Here's why scaling MSC therapies requires maintaining product consistency, potency, and comparability as manufacturing evolves.
-
![success, strategy-GettyImages-1068903328]( "Inside Kyverna's Autoimmune CAR T Platform Beyond SPS")
Inside Kyverna's Autoimmune CAR T Platform Beyond SPS9/16/2026Kyverna's progress suggests that autoimmune CAR T's commercial viability will depend as much on manufacturing readiness and focused indication selection as on its potential to deliver durable, drug-free remission.
-
![Medical healthcare autoimmune disease-GettyImages-1449402295]( "Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?")
Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?9/2/2026The promise of autoimmune CAR T is enormous, but recent safety pauses from Novartis and BMS underscore why the field needs a more patient-centered approach to risk, clinical outcomes, access, and real-world delivery.
-
![Doctor examining mammography-GettyImages-2274267549]( "Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology")
Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology8/28/2026REVTORPYK's FDA approval highlights the broader push toward precision therapies that address complex disease biology, overcome resistance, and deliver more durable patient benefit.
-
![Nanomedicine, oncology medicine, gene targeted therapy, biochemical engineering and pharmaceutical research-GettyImages-2270210340]( "In Vivo CAR T Needs More Than Better Cell Engineering")
In Vivo CAR T Needs More Than Better Cell Engineering8/26/2026In vivo CAR T’s potential to expand access and simplify manufacturing hinges on targeted LNP delivery and solving the durability challenge.
-
![Regulatory T cells panel, Tregs cells test-GettyImages-1498965574]( "Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs")
Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs8/20/2026CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.
-
![Autoimmune disease-GettyImages-893470424]( "Building Antigen-Specific Immune Tolerance For Autoimmune Disease")
Building Antigen-Specific Immune Tolerance For Autoimmune Disease8/10/2026Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.
-
![Success-GettyImages-2279095487]( "Solving Vector Yield Challenges Starts Long Before Manufacturing")
Solving Vector Yield Challenges Starts Long Before Manufacturing7/22/2026Cell & Gene Live panelists take a deep dive into why solving vector yield challenges begins with early biological and manufacturing decisions rather than process optimization alone.
